Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986865 | 0.89 | BRAF (0.46) | BRAFNR1I2GABRA1 | |
| SCHEMBL14865995 | 0.88 | BRAF (0.56) | BRAFNR1I2 | |
| SCHEMBL9986641 | 0.88 | BRAF (0.47) | BRAFNR1I2KCNH2 | |
| SCHEMBL9987059 | 0.87 | BRAF (0.54) | BRAFKCNH2 | |
| SCHEMBL9987845 | 0.84 | BRAF (0.55) | BRAFNR1I2KCNH2GABRA1 | |
| SCHEMBL9986843 | 0.84 | NR1I2 (0.40) | BRAFNR1I2LMNAGABRA1 | |
| SCHEMBL9986869 | 0.82 | LMNA (0.41) | BRAFNR1I2KCNH2LMNAGABRA1 | |
| SCHEMBL9987285 | 0.79 | BRAF (0.49) | BRAFNR1I2 | |
| SCHEMBL14865885 | 0.79 | BRAF (0.54) | BRAFNR1I2 | |
| SCHEMBL9987017 | 0.79 | BRAF (0.48) | BRAFNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585454-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| WO-2011161216-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885NR1I2 693/4885KCNH2 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.